Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Denosumab in fracture healing after distal radius fracture in postmenopausal women
ChiCTR2200066227Phase 4Not yet recruiting
- Sponsor
- Renji Hospital
- Start
- Nov 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of denosumab in osteoporosis (2 arms), sponsored by Renji Hospital. Primary endpoints: Degree of bone healing and Wrist function. Planned start Nov 2022; status: not yet recruiting.
02
Drugs
denosumab
03
Conditions
osteoporosis
Beyond the preview
Go deeper on ChiCTR2200066227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200066227.